SCHEMBL31516636

SCHEMBL31516636

COc1ccc(S(=O)(=O)NC(=O)c2ccc(Cn3cccn3)c(OC)c2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 3/20 0.44
▸ KAT6A Q92794 3/20 0.44
▸ TRAF6 Q9Y4K3 1/20 0.44
▸ HDAC8 Q9BY41 1/20 0.43
▸ GAA P10253 2/20 0.43
▸ RAB9A P51151 1/20 0.42
▸ CYSLTR2 Q9NS75 1/20 0.42
▸ CYSLTR1 Q9Y271 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ FLT1 P17948 1/20 0.42
▸ FLT4 P35916 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ KAT6B Q8WYB5 2/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31516610 0.87 KAT7 (0.44) KAT7KAT6AHDAC8HDAC1HDAC6
SCHEMBL31516689 0.86 CYSLTR2 (0.44) KAT7KAT6AGAACYSLTR2CYSLTR1
SCHEMBL31516651 0.86 KAT7 (0.44) KAT7KAT6AHDAC8GAACYSLTR2
SCHEMBL31172530 0.84 KAT7 (0.55) KAT7KAT6ACYSLTR2CYSLTR1KAT6B
SCHEMBL31691398 0.83 KAT7 (0.43) KAT7KAT6ACYSLTR2CYSLTR1HDAC6
SCHEMBL31172714 0.83 KAT7 (0.52) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516720 0.83 KAT7 (0.46) KAT7KAT6AGAACYSLTR2CYSLTR1
SCHEMBL31172604 0.83 KAT7 (0.44) KAT7KAT6ACYSLTR2CYSLTR1HDAC6
SCHEMBL31172520 0.82 KAT7 (0.49) KAT7KAT6AHDAC1HDAC6KAT6B
SCHEMBL31516644 0.82 GLA (0.45) KAT7KAT6AGAAHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885TRAF6 542/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885TRAF6 542/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885TRAF6 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback